Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?

2024-511435-10-00 Protocol CT‑01-CD-1 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 30 Apr 2025 · Status Ongoing, recruiting · 3 EU/EEA countries · 17 sites · Protocol CT‑01-CD-1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 154
Countries 3
Sites 17

Hepatocellular Carcinoma

Key facts

Sponsor
Captor Therapeutics S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
30 Apr 2025 → ongoing
Decision date (initial)
2024-12-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Hepatocellular Carcinoma

VersionLevelCodeTermSystem organ class
20.0 PT 10073071 Hepatocellular carcinoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Captor Therapeutics S.A.

Sponsor organisation
Captor Therapeutics S.A.
Address
Ul. Dunska 11
City
Wroclaw
Postcode
54-427
Country
Poland

Scientific contact point

Organisation
Captor Therapeutics S.A.
Contact name
Captor Global Regulatory Group

Public contact point

Organisation
Captor Therapeutics S.A.
Contact name
Captor Global Regulatory Group

Locations

3 EU/EEA countries · 17 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 81 8
Germany Authorised, recruitment pending 17 3
Spain Ongoing, recruiting 56 6
Rest of world 0

Investigational sites

France

8 sites · Ongoing, recruiting
Centre Leon Berard
Medical Oncology, 28 Rue Laennec, 69008, Lyon
Centr Georges Francois Leclerc
Medical Oncology, 1 Rue Professeur Marion, 21000, Dijon
Assistance Publique Hopitaux De Paris
Hepatology, 125 Rue De Stalingrad, 93000, Bobigny
Centre Hospitalier Universitaire De Nantes
Hepato-gastroenterology, 1 Place Alexis Ricordeau, 44000, Nantes
Oncopole Claudius Regaud
Medical Digestive Oncology, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Les Hopitaux Universitaires De Strasbourg
Hepato-gastroenterology and endoscopy, 1 Place De L Hopital, Cs 80426, Strasbourg Cedex
Centre Hospitalier Universitaire De Poitiers
Medical Oncology, 2 Rue De La Miletrie, 86000, Poitiers
Institut Gustave Roussy
Early Drug Development Department, 114 Rue Edouard Vaillant, 94800, Villejuif

Germany

3 sites · Authorised, recruitment pending
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
I. Medical Department, Langenbeckstrasse 1, Oberstadt, Mainz
Universitaetsklinikum Heidelberg AöR
Medical Oncology, Im Neuenheimer Feld 460, Neuenheim, Heidelberg
Universitaetsklinikum Leipzig AöR
Medicine II, Hepatology, Haus 6, Liebigstrasse 20a, Leipzig

Spain

6 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital General Universitario De Valencia
Medical Oncology, Avenida Del Tres Cruces 2, 46014, Valencia
Hospital Universitario Miguel Servet
Medical Oncology, Paseo De Isabel La Catolica 1-3, 50009, Zaragoza
Hospital Universitario Fundacion Jimenez Diaz
Medical Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Clinic De Barcelona
Medical Oncology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario La Paz
Medical Oncology, Paseo De La Castellana 261, 28046, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-07-08 2025-07-08
Spain 2025-04-30 2025-05-06

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-22 Spain Acceptable with conditions
2024-12-16
2024-12-16
2 SUBSTANTIAL MODIFICATION SM-1 2025-02-07 Spain Acceptable
2025-03-13
2025-03-14
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-04-30 Spain Acceptable
2025-03-13
2025-04-30
4 NON SUBSTANTIAL MODIFICATION NSM-2 2025-08-05 Spain Acceptable
2025-03-13
2025-08-05
5 SUBSTANTIAL MODIFICATION SM-3 2025-09-23 Spain Acceptable
2026-01-14
2026-01-14
6 SUBSTANTIAL MODIFICATION SM-4 2026-03-30 Acceptable
2026-05-26
2026-05-28